All Melanoma News

Looking Ahead for Melanoma Treatment

While checkpoint inhibitors are a mainstay in the field of advanced melanoma treatment, novel and reimagined therapies offer new hope for this challenging disease state. These therapies include using older agents like interluekin-2 (IL-2) or tumor-infiltrating lymphocytes (TILs) and modifying them to make their activity more potent against melanoma. Additionally, oncolytic vaccines administered into the tumor or systemically can help to sensitize the immune system and improve the response to checkpoint inhibitors.

OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma

Intravenous infusion with OBX-115, an IL-2–free, regulatable, engineered tumor-infiltrating lymphocyte (TIL) cell therapy was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma, according to data from a first-in-human, single-center, phase 1 study (NCT05470283) presented at the 2024 AACR Annual Meeting.

Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

Zeynep Eroglu, MD, medical oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; assistant professor, Department of Oncologic Sciences, the University of South Florida Morsani College of Medicine, discusses unmet needs that currently exist for patients with mutant melanoma, highlighting a phase 1/2 trial (NCT03501368) that evaluated ceritinib (Zykadia) alone and in combination with trametinib (Mekinist) for these patients.

Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma

Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to improve personalized therapies and avoid unnecessary treatments in metastatic uveal melanoma.

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh, discusses the significance of the FDA approval of adjuvant nivolumab (Opdivo) for patients with resected stage IIB or IIC melanoma.

A melanoma subtype emerges from the shadows

Unprotected exposure to ultraviolet (UV) radiation from the sun or other sources is a key risk factor for cutaneous melanoma, the most aggressive form of skin cancer. Having fair skin also increases the risk. The countries with the highest incidence of melanoma, including Australia, New Zealand, and Denmark, are largely composed of populations of European descent (1).

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

Michael R. Migden, MD, dermatologist, professor, Department of Dermatology, Division of Internal Medicine and Head and Neck Surgery, Division of Surgery, and program director, ACGME Fellowship:Micrographic Surgery and Dermatologic Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy data from the phase 1b/2 ARTACUS trial (NCT04349436) evaluating the oncolytic immunotherapy RP1 in patients with advanced non-melanoma cutaneous malignancies who underwent prior solid organ transplant.

Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy.

Managing Immune-Related Toxicities Key to Immunotherapy for Skin Cancer

Incidence of melanoma and keratinocyte (nonmelanoma) skin cancers, such as squamous cell and basal cell carcinomas (SCC and BCC, respectively), continues to increase, but mortality rates are stable or declining because of an explosion of treatment options, including numerous immunotherapy regimens, according to an oral presentation at the 2024 Oncology Nurse Advisor Summit.

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have BRAF V600 mutation–positive disease, a BRAF inhibitor with or without a MEK inhibitor.
C-144-01 Trial

Addition of Lifileucel to Advanced Melanoma Arsenal Marks Milestone for TIL Therapy in Solid Tumor Management

As the first cellular and tumor infiltrating lymphocyte (TIL) therapy product to be approved by the FDA for patients with solid tumors, lifileucel (Amtagvi) could usher in a paradigm shift in advanced melanoma management, thereby paving the way for several other TIL products to gain approval, according to Daniel Olson, MD.

UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma

The addition of the universal cancer vaccine UV1 to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve progression-free survival (PFS) compared with nivolumab plus ipilimumab alone in the first-line treatment of patients with unresectable or metastatic melanoma, failing to meet the primary end point of the phase 2 INITIUM trial (NCT04382664).

Immune networks in tumors found to prime responses to personalized immunotherapy

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T-cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL)

Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery

SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States.

Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma

According to results from a retrospective cohort study, antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse progression-free survival (PFS) and overall survival (OS) results among patients with treatment-naïve cutaneous or mucosal melanoma when compared with antibiotic exposure after initiation of immune checkpoint blockade.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Today, the U.S. Food and Drug Administration approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor).

Imaging just one week after starting treatment can predict melanoma response to immunotherapy

While the standard timing for imaging patients’ tumors after immunotherapy is three months, researchers found that imaging patients with melanoma after just one week of treatment illuminated metabolic changes in their tumors that corresponded with a response to the treatment and longer survival, according to new research from the Perelman School of Medicine

SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment

ROTTERDAM, Netherlands and SAN DIEGO, Jan. 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European Patent Office (EPO) has granted European Patent No. 3827101, marking a groundbreaking advancement in the field of cancer diagnostics and personalized treatment.

Dr Possik on the Importance of Diversity and Equity in Melanoma Research

Patricia A. Possik, PhD, assistant investigator, Division of Cellular Biology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research, including how a more diverse research landscape can influence the efficacy and relevance of treatment approaches in acral lentiginous melanoma.

3D scanner leaves no melanoma undetected

Source: Medical Republic, January 2024 A3D scanner that captures every nook and cranny of a patient’s skin will be available to NSW Mid North Coast residents next year to improve early detection and boost melanoma research. The scanner will be one of 15 whole-body imaging machines to be rolled out…

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference – Hawaii®

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference – Hawaii, being held Jan. 12-17 in Honolulu, Hawaii.

ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

The addition of a personalized mRNA vaccine to standard-of-care (SOC) pembrolizumab (Keytruda) improved survival outcomes vs pembrolizumab alone in resected high-risk melanoma, and monitoring ctDNA patterns over time can provide valuable insights into the degree of benefit patients can expect to achieve from the approach, according to Jeffrey S. Weber, MD, PhD.

Wistar scientists enhance cell-based therapy to destroy solid tumors

PHILADELPHIA—(Dec. 13, 2023)—Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer. Led by Dr. Hildegund C.J. Ertl — a professor in The Wistar Institute’s Vaccine & Immunotherapy Center — the team has proven an exciting concept: that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors, as described in their new paper, “Treatment with the PPAR? agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma,” published in Molecular Therapy Oncolytics.

OBX-115 Elicits Responses in Advanced or Metastatic Melanoma

The tumor-infiltrating lymphocyte (TIL) cell therapy OBX-115 produced responses with no dose-limiting toxicities (DLTs) in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor (ICI) therapy, according to topline data from a phase 1 trial (NCT05470283).

SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of regulatory T cells (Tregs), monocytic myeloid-derived suppressor cells (M-MDSCs), and M2 macrophages in liver metastases in patients with uveal melanoma, according to data from the phase 1 PERIO-01 trial (NCT04935229) presented at the 2023 SITC Annual Meeting.

Opdualag licensed for patients with advanced melanoma

This is a cancer medicine used to treat advanced melanoma, a type of skin cancer that can spread to other areas of the body. The main risk factor for melanoma is exposure to ultraviolet light, which comes from the sun and is used in sunbeds. Around 17,000 cases of melanoma are diagnosed every year in the UK, although not all of those are advanced melanoma.

Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma

Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte (TIL) therapy in patients with advanced, metastatic melanoma, according to data from a phase 1 trial (NCT04217473) presented at the 2023 ESMO Immuno-Oncology Annual Congress.

Bemcentinib Plus SOC Is Well Tolerated, But Does Not Improve Efficacy in Metastatic Melanoma

The addition of bemcentinib (BGB324) to the standard-of-care (SOC) therapies of pembrolizumab (Keytruda) or dabrafenib (Tafinlar) plus trametinib (Mekinist) was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) vs SOC alone, according to data from the phase 1b/2 BGBIL006 trial (NCT02872259).

Study: Key mechanisms of action differences in immune checkpoint inhibitor combination therapies for advanced melanoma

Checkpoint inhibitors that activate the immune system to target cancer cells for destruction have revolutionized the treatment landscape for patients with advanced melanoma, leading to more options and improved patient survival. Despite the approval of several immune checkpoint inhibitor regimens for melanoma, scientists do not completely understand their anticancer effects.

Dr Weber on Survival Outcomes With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

S. Weber, MD, PhD, deputy director, codirector, the Melanoma Research Program, NYU Langone Perlmutter Cancer Center, Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881) of mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) in resected high-risk melanoma.

3-Year Overall Survival With Tebentafusp in Previously Untreated Advanced Uveal Melanoma

In an analysis presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA50) and reported in The New England Journal of Medicine by Jessica C. Hassel, MD, and colleagues, overall survival at 3 years in the phase III IMCgp100-202 trial continued to favor tebentafusp-tebn over investigator’s choice of treatment in previously untreated patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Assay (CP-GEP) in melanoma care

ROTTERDAM, Netherlands and SAN DIEGO, Oct. 31, 2023 /PRNewswire/ — SkylineDx an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, proudly announces the successful clinical validation and implementation of the clinicopathologic and gene expression profile (CP-GEP) model in a multicenter Dutch study focused on patients with melanoma.

Dr Buchbinder on Treatment With Nivolumab Maintenance Following irAEs in Melanoma

Elizabeth Buchbinder, MD, assistant professor, Medicine, Harvard Medical School, senior physician, Medical Oncology, Dana-Farber Cancer Institute, discusses the investigation of treatment with nivolumab (Opdivo) maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects (irAEs) associated with combination therapy with nivolumab and ipilimumab (Yervoy).

Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

The panelists emphasize the importance of obtaining tissue for BRAF-mutation testing and dedicated tissue tracking in patients with metastatic melanoma, with immunohistochemistry followed by confirmatory next-generation sequencing, and discuss the promise of liquid biopsies like ctDNA as a future biomarker tracking modality.

Multidisciplinary Consideration of Frontline Modalities Should Guide Decisions in Melanoma With In-Transit Metastases

Danielle K. DePalo, MD, explains the lack of research directly comparing first-line treatment options for patients with unresectable melanoma in-transit metastases, expands on the safety and efficacy of 3 treatment modalities for these patients, and underscores the need for more data to inform the management of these patients.

mRNA Vaccine Continues to Show Promise in Resected Melanoma

The individualized neoantigen therapy mRNA-4157 (V940), combined with pembrolizumab (Keytruda), improved relapse-free survival (RFS) and distant metastasis-free survival (DMFS) compared with pembrolizumab alone in patients with high-risk resected melanoma, according to findings from the phase 2 KEYNOTE-942 trial (NCT03897881) presented at the 2023 European Society for Medical Oncology Congress (ESMO).

Detecting Melanoma Copy Number Variation: Novel CDKN2A Quantitation Using Droplet Digital PCR

Doctors can often identify signs of a melanoma through a visual examination of a patient’s skin, by using a dermoscope or other tools. But additional information is sometimes needed to make a precise diagnosis, according to SciBase, a medical tech company based in Stockholm, Sweden—which has developed a device it says provides exactly that.

FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Nurse Practitioner Lisa Kottschade Discusses Immune-Related Adverse Events, Biomarkers

Lisa A. Kottschade, RN, CNP, FAPO, discussed immune-related adverse events, which she presented on at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event hosted by Minnesota Oncology in Minneapolis, Minnesota, on September 12. Kottschade, who is primarily interested in malignant melanoma treatment, also discussed the use of biomarkers.

Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma

Alexander I. Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute, director, Thoracic and Phase I Program, clinical assistant professor, Johns Hopkins School of Medicine, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimab-rwlc (Libtayo) in patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study (NCT03005782).

Melanoma: causes, identification and diagnosis

The British broadcaster and DJ, Chris Evans, has revealed that he has been diagnosed with a skin cancer called a “melanoma”. The 57-year-old says that he was tested for the disease after his masseuse noticed a mark on his shin. So, what exactly is melanoma? Julia Newton-Bishop is a professor of dermatology at the University of Leeds…

Dr Monga on the Background of Investigating PRT811 in Glioma and Melanoma

Varun Monga, MD, clinical associate professor, internal medicine, hematology, oncology, and blood and marrow transplantation, University of Iowa, discusses the background for investigating the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in a phase 1 study (NCT04089449) in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.

2023 MRV Scientific Exchange Meeting

Melanoma Research Victoria warmly invites you to attend the 2023 MRV Scientific Exchange Meeting. Wednesday 6th December 2023 6.00pm-8.00pm Innovation & Education Hub (Lecture Theatre), The Alfred, 55 Commercial Road, Melbourne, 3004 OR ONLINE via Microsoft Teams All members of the melanoma community, including: patients; carers; consumers; clinicians; researchers; health professionals;…

Dr McKean on the Rationale For Evaluating LAG-3 Inhibitors in Advanced Melanoma

Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination’s efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.

A drug for heart conditions improves efficacy of melanoma therapies

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, ??Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, ??Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

Pembrolizumab Elicits Long-Term Survival Benefit in Advanced Melanoma

Pembrolizumab (Keytruda) demonstrated long-term survival benefit compared with ipilimumab (Yervoy) in patients with unresectable stage III/IV melanoma who received up to 1 prior systemic therapy, according to 7-year follow-up data from the phase 3 KEYNOTE-006 (NCT01866319) trial, which included some patients who transitioned to the phase 3 KEYNOTE-587 (NCT03486873) extension study, published in the Journal of Clinical Oncology.

A medication used for heart conditions improves the efficacy of current treatments for melanoma in mouse models

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma

Ryan J. Sullivan, MD, associate professor of medicine, Harvard Medical School, associate director. the Melanoma Program, Massachusetts General Cancer, discusses the early reduction of circulating tumor DNA (ctDNA) in patients with metastatic uveal melanoma treated with tebentafusp-tebn (Kimmtrak) and shares how these reductions could correlate with longer overall survival (OS) in patients with a best response of stable disease.

Atezolizumab, Vemurafenib, and Cobimetinib in Patients With BRAF V600–Mutated Melanoma and CNS Metastases

A revised report of findings from the phase II TRICOTEL study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma and central nervous system (CNS) metastases was published in The Lancet Oncology by Reinhard Dummer, MD, and colleagues. The first version of trial findings, published online in August 2022, was retracted.

Dr Buchbinder on Treatment Decisions After Severe irAEs With Nivolumab/Ipilimumab in Melanoma

Elizabeth Buchbinder, MD, assistant professor, Medicine, Harvard Medical School, senior physician, Medical Oncology, Dana-Farber Cancer Institute, discusses the rationale for investigating nivolumab (Opdivo) maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects (irAEs) due to combination therapy with nivolumab and ipilimumab (Yervoy), and details the findings of this investigation.

Fecal transplants show promise in improving melanoma treatment

In a world-first clinical trial published in the journal Nature Medicine, a multi-centre study from Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal (CHUM) and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

Melanoma Research Alliance’s RARE Registry for Acral & Mucosal Melanoma Surpasses Industry-Leading 100-Patient Milestone

WASHINGTON, July 10, 2023 /PRNewswire/ — The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that the RARE Registry for acral and mucosal melanoma has officially surpassed 100 patients, making it the largest registry of its kind in the world and marking an important milestone in advancing cutting-edge research for these rare and difficult-to-treat melanoma subtypes.

BRAF Class II and NRAS-Targeting Drug Shows Promising Efficacy, Safety, and Tolerability in Early Phase I Data

Exarafenib, a pan-RAF inhibitor being investigated as a monotherapy in BRAF and NRAS-driven solid tumors by Kinnate Biopharma, was well-tolerated and demonstrated early signs of activity with durable responses in various patient populations, including those with BRAF Class II and NRAS-mutant melanoma, according to early Phase I trial results.

Size, Location, Affiliation of Practice Impact Immunotherapy Adoption Rates

According to an analysis of Medicare fee-for- service beneficiaries treated with chemotherapy between 2010 and 2017, the speed at which immunotherapy is adopted by oncology practices depends on their size, location, and affiliation (rural or urban, independent or health system–affiliated, academic or nonacademic, smaller or larger [1 to 5 physicians vs 6 or more]).

Development of FHD-286 Monotherapy Will Not Continue in Metastatic Uveal Melanoma

Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial (NCT04879017), further development in this indication will not be pursued, according to an announcement from Foghorn Therapeutics.

Researchers discovered how melanoma changes its environment to support metastasis

Newswise — A fresh analysis performed at Tel Aviv University and the Sheba Medical Center unveils how melanoma tumor cells impact their nearby surroundings to aid their requirements – by generating fresh lymph channels in the dermis to penetrate further into the skin and extend throughout the body. The scientists hold the view that this novel finding might aid in the advancement of an immunization against this fatal cancer.

Combination of mRNA-4157 With Pembrolizumab Improves Survival in Melanoma

In the phase 2 KEYNOTE-942 trial (NCT03897881), mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) led to a reduced risk of developing distant metastasis or death by approximately 65% vs with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings presented at the 2023 ASCO Annual Meeting.

After Decades of Limited Treatment Options, New Treatments Are Showing Promise for Non-Melanoma Skin Cancer

In an interview with Pharmacy Times at the Oncology Pharmacists Connect conference, Heather Armbruster, PharmD, BCOP, outpatient clinical pharmacy manager at Ohio State University Comprehensive Cancer Center, discussed the growing armamentarium of treatment options for non-melanoma skin cancers. With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

Step Closer to Beating Melanoma?

A new study conducted at Tel Aviv University and the Sheba Medical Center reveals how melanoma cancer cells affect their close environment to support their needs – by forming new lymph vessels in the dermis to go deeper into the skin and spread through the body. The

Cost-effectiveness of second-line ipilimumab for metastatic melanoma: a real-world population-based cohort study of resource utilization

Background — The efficacy-effectiveness gap between randomized trial and real-world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns raised by health technology assessment agencies (HTAs).